Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 13/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308050 | 1.00 | FLT3 (0.58) | FLT3CCNA2CDK2CCNA1KDR | |
| SCHEMBL4311607 | 0.89 | ALDH1A1 (0.51) | FLT3CCNA2CDK2CCNA1KDR | |
| SCHEMBL4311615 | 0.89 | ALDH1A1 (0.51) | FLT3CCNA2CDK2CCNA1KDR | |
| SCHEMBL4313440 | 0.84 | CHEK1 (0.47) | FLT3CCNA2CDK2CCNA1KDR | |
| SCHEMBL4313444 | 0.84 | CHEK1 (0.47) | FLT3CCNA2CDK2CCNA1KDR | |
| SCHEMBL4309474 | 0.83 | KDR (0.51) | FLT3CCNA2CDK2CCNA1KDR | |
| SCHEMBL4309480 | 0.83 | KDR (0.51) | FLT3CCNA2CDK2CCNA1KDR | |
| SCHEMBL4329156 | 0.82 | KDM4E (0.40) | FLT3CCNA2CDK2CCNA1KDR | |
| SCHEMBL4329167 | 0.82 | KDM4E (0.40) | FLT3CCNA2CDK2CCNA1KDR | |
| SCHEMBL4316596 | 0.81 | TSHR (0.51) | FLT3KDRFGFR1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101111483-B | IGF-1R inhibitors | KYOWA HAKKO KIRIN CO.,LTD. (JP) | 2011-12-14 | — | — | CN | disclosed |
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| CN-101111483-A | IGF-1R inhibitors | KYOWA HAKKO KOGYO KK (JP) | 2008-01-23 | — | — | CN | disclosed |
| EP-1847532-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054508-A1 | IGF-1R INHIBITOR | IGF1R, IGFBP5, IGFBP1 | FLT3 390/4885CCNA2 3682/4885CDK2 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.